Shoreline Biosciences
Qin Li has a strong background in translational pharmacology and oncology. They started their career at Moores Cancer Center as a Postdoctoral Scholar, where they focused on researching glioblastomas and identifying a novel angiogenic factor. Qin then moved on to BioDuro-Sundia, where they held roles as a Senior Oncology Scientist and later as an Associate Director in Oncology. Currently, Qin is working at Shoreline Biosciences, Inc. as a Sr. Scientist and has been promoted to the role of Principal Scientist in Translational Pharmacology.
Qin Li completed a Bachelor of Science (B.S.) in Biotechnology from Beijing Normal University, followed by a Master of Science (M.S.) in Biochemistry from the University of Saskatchewan. Qin then obtained a Doctor of Philosophy (Ph.D.) in Genetics from UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences in 2013.
Shoreline Biosciences
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.